Aastrom Announces Appointments of Dr. Ross Tubo as Chief Scientific Officer and Dr. David Recker as Chief Medical Officer
April 01 2014 - 8:30AM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific, expanded multicellular therapies for the
treatment of severe, chronic cardiovascular diseases, today
announced the appointments of Ross Tubo, PhD, as chief scientific
officer and David Recker, MD, FACR, FACP, as chief medical officer
of Aastrom.
Dr. Tubo was formerly vice president of stem cell and chemokine
biology at Genzyme, where he directed the research and development
programs for two of the first FDA-approved autologous cellular
therapies. He also led an interdisciplinary research program to
study the cellular and molecular biology of mesenchymal stem cells
and their reparative properties in a range of areas, including
oncology, inflammation and autoimmune disease. Additionally,
as founder of Research Translation, LLC, Dr. Tubo provided senior
level consulting services to several leading companies developing
cell therapies and regenerative medicines. He received his
doctorate and master's degree from the State University of New York
at Buffalo and completed a postdoctoral fellowship at Harvard
Medical School.
Dr. Recker joins Aastrom with more than 20 years of
experience in drug development. He most recently served as a senior
vice president of clinical sciences at Takeda Global Research and
Development, where he led a multi-regional clinical organization
responsible for designing and implementing global clinical
development strategies for a variety of products in a range of
therapeutic areas. Dr. Recker has played a lead role in multiple
successful global regulatory filings. He holds an MD with
distinction from the University of Michigan, where he was chief
resident in internal medicine. He completed his fellowship at the
National Institutes of Health.
"The addition of Dr. Tubo and Dr. Recker significantly advances
our goal of building the foremost research and development
leadership team in the cell therapy and regenerative medicine
field," said Nick Colangelo, president and chief executive
officer of Aastrom. "Ross is a recognized pioneer in the
development and registration of cell therapies and has deep
expertise in the biology of mesenchymal stem cell therapies and
their potential therapeutic applications. Dave is a highly
accomplished industry veteran who has successfully managed a wide
range of global clinical development programs and multiple
successful regulatory filings. Together they will play a key role
in advancing our current clinical development programs, identifying
new indications for ixmyelocel-T and pursuing promising new
business opportunities for Aastrom in the years ahead."
About Aastrom Biosciences
Aastrom Biosciences is the leader in developing
patient-specific, expanded multicellular therapies for use in the
treatment of patients with severe, chronic cardiovascular
diseases. The company's proprietary cell-processing technology
enables the manufacture of ixmyelocel-T, a patient-specific
multicellular therapy expanded from a patient's own bone marrow and
delivered directly to damaged tissues. Aastrom has advanced
ixmyelocel-T into late-stage clinical development, including the
Phase 2b ixCELL-DCM clinical trial in patients with advanced heart
failure due to ischemic dilated cardiomyopathy. For more
information, please visit Aastrom's website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including,
without limitation, statements concerning clinical trial plans and
progress, objectives and expectations, clinical activity timing,
intended product development, the performance and contribution of
certain individuals and expected timing of collecting and analyzing
treatment data, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "anticipates,"
"intends," "estimates," "plans," "expects," "we believe," "we
intend," and similar words or phrases, or future or conditional
verbs such as "will," "would," "should," "potential," "could,"
"may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with the
closing of the offering described herein, Aastrom's intended use of
proceeds in connection with the offering, clinical trial and
product development activities, regulatory approval requirements,
competitive developments, and the availability of resources and the
allocation of resources among different potential uses. These
and other significant factors are discussed in greater detail in
Aastrom's Registration Statement on Form S-1 described above,
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and
other filings with the Securities and Exchange Commission. These
forward-looking statements reflect management's current views and
Aastrom does not undertake to update any of these forward-looking
statements to reflect a change in its views or events or
circumstances that occur after the date of this release except as
required by law.
CONTACT: Media contact:
Andrea Coan
Berry & Company
acoan@berrypr.com
(212) 253-8881
Investor contact:
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Oct 2023 to Oct 2024